IN2012DN01261A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01261A
IN2012DN01261A IN1261DEN2012A IN2012DN01261A IN 2012DN01261 A IN2012DN01261 A IN 2012DN01261A IN 1261DEN2012 A IN1261DEN2012 A IN 1261DEN2012A IN 2012DN01261 A IN2012DN01261 A IN 2012DN01261A
Authority
IN
India
Prior art keywords
macitentan
bosentan
receptor antagonist
endothelin receptor
radiotherapy
Prior art date
Application number
Inventor
Isaiah J Fidler
Sun-Jin Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of IN2012DN01261A publication Critical patent/IN2012DN01261A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Abstract

The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.
IN1261DEN2012 2009-08-10 2010-08-09 IN2012DN01261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
PCT/US2010/044832 WO2011019630A2 (en) 2009-08-10 2010-08-09 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors

Publications (1)

Publication Number Publication Date
IN2012DN01261A true IN2012DN01261A (en) 2015-05-15

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1261DEN2012 IN2012DN01261A (en) 2009-08-10 2010-08-09

Country Status (28)

Country Link
US (2) US8999934B2 (en)
EP (1) EP2464218B1 (en)
JP (1) JP2013501791A (en)
KR (1) KR20120088665A (en)
CN (1) CN102510719B (en)
AU (1) AU2010282744B2 (en)
BR (1) BR112012003103A2 (en)
CA (1) CA2770397A1 (en)
CL (1) CL2012000333A1 (en)
DK (1) DK2464218T3 (en)
EA (1) EA023864B1 (en)
ES (1) ES2543280T3 (en)
HK (1) HK1171336A1 (en)
HR (1) HRP20150890T1 (en)
HU (1) HUE026005T2 (en)
IL (1) IL217915A0 (en)
IN (1) IN2012DN01261A (en)
MA (1) MA33571B1 (en)
MX (1) MX2012001562A (en)
NZ (1) NZ598078A (en)
PL (1) PL2464218T3 (en)
PT (1) PT2464218E (en)
SG (1) SG178828A1 (en)
SI (1) SI2464218T1 (en)
TN (1) TN2012000054A1 (en)
TW (1) TWI483938B (en)
WO (1) WO2011019630A2 (en)
ZA (1) ZA201200980B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013008798A (en) * 2011-02-04 2013-10-17 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme.
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
EP3265091A4 (en) * 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
MY190034A (en) 2015-03-06 2022-03-22 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
JP6996728B2 (en) * 2016-01-07 2022-01-17 学校法人自治医科大学 Adeno-associated virus vector for glucose transporter 1 expression
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
WO2017209272A1 (en) * 2016-06-03 2017-12-07 国立大学法人東京大学 Cancer metastasis inhibitor
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
SG11201907023UA (en) 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
CA3087009A1 (en) 2018-01-12 2019-07-18 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109232546B (en) 2018-09-25 2020-09-04 中国人民解放军总医院 Medical application of pyrimidine sulfonamide derivative
CN112062857A (en) * 2019-06-10 2020-12-11 鸿运华宁（杭州）生物医药有限公司 Fusion protein of ETA antibody and BNP, and pharmaceutical composition and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229403B1 (en) 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
DK1928409T3 (en) * 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd STABLE PHARMACEUTICAL COMPOSITION INCLUDING PYRIMIDINE SULFAMIDE
RU2494736C2 (en) 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Combination containing paclitaxel for treating ovarian cancer
MX2013008798A (en) 2011-02-04 2013-10-17 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme.

Also Published As

Publication number Publication date
BR112012003103A2 (en) 2016-04-19
WO2011019630A3 (en) 2011-06-03
ZA201200980B (en) 2012-10-31
EA023864B1 (en) 2016-07-29
MA33571B1 (en) 2012-09-01
TN2012000054A1 (en) 2013-09-19
HRP20150890T1 (en) 2015-09-25
JP2013501791A (en) 2013-01-17
KR20120088665A (en) 2012-08-08
US8999934B2 (en) 2015-04-07
US20150352113A1 (en) 2015-12-10
HUE026005T2 (en) 2016-04-28
MX2012001562A (en) 2013-01-29
PL2464218T3 (en) 2015-12-31
SI2464218T1 (en) 2015-10-30
HK1171336A1 (en) 2013-03-28
EP2464218A2 (en) 2012-06-20
IL217915A0 (en) 2012-03-29
SG178828A1 (en) 2012-04-27
WO2011019630A2 (en) 2011-02-17
CL2012000333A1 (en) 2013-01-25
ES2543280T3 (en) 2015-08-17
EP2464218B1 (en) 2015-05-27
CN102510719B (en) 2015-07-22
EA201270264A1 (en) 2013-02-28
AU2010282744A1 (en) 2012-03-22
AU2010282744B2 (en) 2014-08-28
CN102510719A (en) 2012-06-20
CA2770397A1 (en) 2011-02-17
NZ598078A (en) 2013-07-26
PT2464218E (en) 2015-09-16
US20120144510A1 (en) 2012-06-07
DK2464218T3 (en) 2015-07-20
TW201109315A (en) 2011-03-16
TWI483938B (en) 2015-05-11

Similar Documents

Publication Publication Date Title
IN2012DN01261A (en)
MX2011008450A (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof.
IN2012DN02177A (en)
IN2012DN02702A (en)
IN2012DN00754A (en)
MX2011007930A (en) Crystalline insulin-conjugates.
TN2012000082A1 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
GB201017345D0 (en) Receptor antagonists
MX2013002048A (en) Conjugates, particles, compositions, and related methods.
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
MX2011011950A (en) Sublingual dexmedetomidine compositions and methods of use thereof.
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
MX2013004981A (en) Compositions and methods for the delivery of therapeutics.
MX2011006725A (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies.
MX2013003599A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies.
TN2011000428A1 (en) Uses of nk receptor antagonists
EP2576575A4 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
PH12017501767A1 (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
GB201212586D0 (en) Cancer treatment
UA96037C2 (en) Use of interleukin-1 receptor antagonist as an antialcoholic agent
CY1116512T1 (en) TREATMENT OF BRAIN TRANSMISSIONS WITH SUSPENSIONS OF ENDOTHYLINE RECEPTORS IN CONNECTION WITH A CYTAROTOXIC FACTOR CHEMISTER
UA96048C2 (en) Use of interleukin-1 receptor antagonist as an frigoprotective agent
UA41922U (en) Use of altan as radioprotector